Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015

Thamir M Alshammari1 Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia;2 Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia;3 Saudi Food and Drug Authority, Riyadh, Saudi ArabiaCorrespondence[email protected]

Sondus I Ata4 Pharmacy Services, King Saud University Medical City, Riyadh, Saudi Arabia

Mansour Adam Mahmoud5 Department of Clinical Pharmacy, College of Pharmacy, Taibah University, Medina, Saudi Arabia

Tariq M Alhawassi2 Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia;4 Pharmacy Services, King Saud University Medical City, Riyadh, Saudi Arabia;6 Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Hisham S Aljadhey3 Saudi Food and Drug Authority, Riyadh, Saudi Arabia

Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date